Advances in the pharmacotherapy of Alzheimer's disease.
The authors reviewed the literature on the agents proposed for the treatment of Alzheimer's disease (AD). Different classes of drugs have been tested for this indication including psychostimulants, anticoagulants, vasodilators, hyperbaric oxygen, hormones, nootropics, cholinomimetics, monoaminergics and neuropeptides without conclusive evidence of being beneficial for the treatment of this condition. Among the cholinomimetics recent research data seems to indicate that they might produce modest benefits in mild-to-moderate AD patients. Recently, other drugs have also been proposed including neurotrophic factors, phosphatidylserine, angiotension [corrected] converting enzyme (ACE) inhibitors, calcium channel blockers, acetyl-L-carnitine, xanthine derivatives, anti-inflammatory agents, aluminum chelate agents, and D-cycloserine. Of these new strategies few hold promise of more substantial benefits for AD, with the possibility of altering the course of the disease, but these drugs await confirmatory trials.
Soares
J C
JC
Western Psychiatric Institute and Clinic, University of Pittsburgh, PA 15213.
Gershon
S
S
D000544:Alzheimer Disease / Q000150:complications / Q000188:drug therapy*; D003072:Cognition Disorders / Q000209:etiology; D004358:Drug Therapy; D006801:Humans